CG Oncology, Inc. (CGON)
(Delayed Data from NSDQ)
$31.33 USD
-1.74 (-5.26%)
Updated Jul 29, 2024 04:00 PM ET
After-Market: $31.30 -0.03 (-0.10%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth A Momentum D VGM
Balance Sheet
Fiscal Year End for CG Oncology, Inc falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 188 | 143 | -99,999 | -99,999 | -99,999 |
Receivables | 0 | 0 | NA | NA | NA |
Notes Receivable | 0 | 0 | NA | NA | NA |
Inventories | 0 | 0 | NA | NA | NA |
Other Current Assets | 6 | 3 | NA | NA | NA |
Total Current Assets | 194 | 147 | NA | NA | NA |
Net Property & Equipment | 0 | 0 | NA | NA | NA |
Investments & Advances | 0 | 0 | NA | NA | NA |
Other Non-Current Assets | 0 | 0 | NA | NA | NA |
Deferred Charges | 5 | 0 | NA | NA | NA |
Intangibles | 0 | 0 | NA | NA | NA |
Deposits & Other Assets | 0 | 0 | NA | NA | NA |
Total Assets | 199 | 148 | NA | NA | NA |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | NA | NA | NA |
Accounts Payable | 3 | 1 | NA | NA | NA |
Current Portion Long-Term Debt | 0 | 9 | NA | NA | NA |
Current Portion Capital Leases | 0 | 0 | NA | NA | NA |
Accrued Expenses | 10 | 5 | NA | NA | NA |
Income Taxes Payable | 0 | 0 | NA | NA | NA |
Other Current Liabilities | 0 | 0 | NA | NA | NA |
Total Current Liabilities | 14 | 15 | NA | NA | NA |
Mortgages | 0 | 0 | NA | NA | NA |
Deferred Taxes/Income | 0 | 0 | NA | NA | NA |
Convertible Debt | 0 | 0 | NA | NA | NA |
Long-Term Debt | 0 | 7 | NA | NA | NA |
Non-Current Capital Leases | 0 | 0 | NA | NA | NA |
Other Non-Current Liabilities | 308 | 203 | NA | NA | NA |
Minority Interest (Liabilities) | 0 | 0 | NA | NA | NA |
Total Liabilities | 322 | 225 | NA | NA | NA |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | NA | NA | NA |
Common Stock (Par) | 0 | 0 | NA | NA | NA |
Capital Surplus | 7 | 4 | NA | NA | NA |
Retained Earnings | -130 | -81 | NA | NA | NA |
Other Equity | 0 | 0 | NA | NA | NA |
Treasury Stock | 0 | 0 | NA | NA | NA |
Total Shareholder's Equity | -123 | -78 | NA | NA | NA |
Total Liabilities & Shareholder's Equity | 199 | 148 | NA | NA | NA |
Total Common Equity | -123 | -78 | 0 | 0 | 0 |
Shares Outstanding | 63.40 | NA | NA | NA | NA |
Book Value Per Share | -1.94 | 0.00 | 0.00 | 0.00 | 0.00 |
Fiscal Year End for CG Oncology, Inc falls in the month of December.
All items in Millions except Per Share data.
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | -99,999 | 567 | 188 | -99,999 | -99,999 |
Receivables | NA | 0 | 0 | NA | NA |
Notes Receivable | NA | 0 | 0 | NA | NA |
Inventories | NA | 0 | 0 | NA | NA |
Other Current Assets | NA | 12 | 6 | NA | NA |
Total Current Assets | NA | 579 | 194 | NA | NA |
Net Property & Equipment | NA | 0 | 0 | NA | NA |
Investments & Advances | NA | 0 | 0 | NA | NA |
Other Non-Current Assets | NA | 0 | 0 | NA | NA |
Deferred Charges | NA | 0 | 5 | NA | NA |
Intangibles | NA | 0 | 0 | NA | NA |
Deposits & Other Assets | NA | 0 | 0 | NA | NA |
Total Assets | NA | 579 | 199 | NA | NA |
Liabilities & Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Notes Payable | NA | 0 | 0 | NA | NA |
Accounts Payable | NA | 5 | 3 | NA | NA |
Current Portion Long-Term Debt | NA | 0 | 0 | NA | NA |
Current Portion Capital Leases | NA | 0 | 0 | NA | NA |
Accrued Expenses | NA | 5 | 10 | NA | NA |
Income Taxes Payable | NA | 0 | 0 | NA | NA |
Other Current Liabilities | NA | 0 | 0 | NA | NA |
Total Current Liabilities | NA | 10 | 14 | NA | NA |
Mortgages | NA | 0 | 0 | NA | NA |
Deferred Taxes/Income | NA | 0 | 0 | NA | NA |
Convertible Debt | NA | 0 | 0 | NA | NA |
Long-Term Debt | NA | 0 | 0 | NA | NA |
Non-Current Capital Leases | NA | 0 | 0 | NA | NA |
Other Non-Current Liabilities | NA | 308 | NA | NA | |
Minority Interest (Liabilities) | NA | 0 | 0 | NA | NA |
Total Liabilities | NA | 10 | 322 | NA | NA |
Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Preferred Stock | NA | 0 | 0 | NA | NA |
Common Stock (Par) | NA | 0 | 0 | NA | NA |
Capital Surplus | NA | 716 | 7 | NA | NA |
Retained Earnings | NA | -147 | -130 | NA | NA |
Other Equity | NA | 0 | 0 | NA | NA |
Treasury Stock | NA | 0 | 0 | NA | NA |
Total Shareholder's Equity | NA | 569 | -123 | NA | NA |
Total Liabilities & Shareholder's Equity | NA | 579 | 199 | NA | NA |
Total Common Equity | 0 | 569 | -123 | 0 | 0 |
Shares Outstanding | 66.60 | 66.60 | 63.40 | NA | NA |
Book Value Per Share | 0.00 | 8.54 | -1.94 | 0.00 | 0.00 |